The causes and treatment of bone loss associated with carcinoma of the breast.

[1]  Mo Chen,et al.  REGULATION OF BONE REMODELING , 2005 .

[2]  R. Greil,et al.  P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial , 2005 .

[3]  P. Lønning,et al.  Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study , 2004 .

[4]  P. Lønning,et al.  Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Kanis,et al.  Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled 3‐Year Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[7]  M. Piccart,et al.  First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group , 2004 .

[8]  R. Coleman.  Effect of anastrozole on bone mineral density and bone fractures: results from the ‘Arimidex’ (anastrozole), Tamoxifen, alone or in combination (ATAC) trial , 2004 .

[9]  L. Holmberg,et al.  HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped , 2004, The Lancet.

[10]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[11]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[12]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[14]  A. Howell.  676 An assessment of fracture rates over time (between 6 and 48 months) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in combination) trial , 2003 .

[15]  Paul J. Williams,et al.  C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. , 2003, Cancer research.

[16]  E. Seregni,et al.  Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. , 2003, Anticancer research.

[17]  J. Kanis,et al.  Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  A. Giuliano,et al.  The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. , 2003, The American journal of medicine.

[19]  W. Leslie,et al.  Contribution of clinical risk factors to bone density-based absolute fracture risk assessment in postmenopausal women , 2003, Osteoporosis International.

[20]  G. Leb,et al.  Normative data of bone mineral density in an unselected adult Austrian population , 2003, European journal of clinical investigation.

[21]  A. Hofman,et al.  Bone mineral density and the risk of breast cancer: the Rotterdam Study. , 2003, Bone.

[22]  P. Delmas,et al.  Review of ibandronate in the treatment of osteoporosis , 2003, Expert opinion on pharmacotherapy.

[23]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[24]  C Ronald MacKenzie,et al.  Hip fractures among the elderly: causes, consequences and control , 2003, Ageing Research Reviews.

[25]  C. Miyaura,et al.  Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. , 2003, Biochemical and biophysical research communications.

[26]  S. Cummings,et al.  Clinical use of bone densitometry: scientific review. , 2002, JAMA.

[27]  Janet E Brown,et al.  Assessment of the effects of breast cancer on bone and the response to therapy. , 2002, Breast.

[28]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Dargent-Molina,et al.  Use of Clinical Risk Factors in Elderly Women with Low Bone Mineral Density to Identify Women at Higher Risk of Hip Fracture: The EPIDOS Prospective Study , 2002, Osteoporosis International.

[30]  E. Chao,et al.  The effect of a doxorubicin, cisplatin and ifosfamide combination chemotherapy on bone turnover. , 2002, Anticancer research.

[31]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[32]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[33]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[34]  R. Coleman.  The clinical use of bone resorption markers in patients with malignant bone disease , 2002, Cancer.

[35]  Jacques P. Brown,et al.  The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women , 2002, BMC musculoskeletal disorders.

[36]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[37]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  O. Johnell,et al.  Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds , 2001, Osteoporosis International.

[39]  C. Blomqvist,et al.  Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. , 2001, European journal of cancer.

[40]  R. Cancedda,et al.  High‐dose chemotherapy shows a dose‐dependent toxicity to bone marrow osteoprogenitors , 2001, Cancer.

[41]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Morgan,et al.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[46]  J A Kanis,et al.  Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. , 2001, Bone.

[47]  L. Raisz.  Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. , 2001, The American journal of medicine.

[48]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[49]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[52]  D. Baran,et al.  Reconciling Quantitative Ultrasound of the Calcaneus with X‐Ray‐Based Measurements of the Central Skeleton , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[54]  L. Pylkkänen,et al.  Timing of food intake has a marked effect on the bioavailability of clodronate. , 2000, Bone.

[55]  R. Cumming,et al.  Systematic Review of Randomized Trials of the Effect of Exercise on Bone Mass in Pre- and Postmenopausal Women , 2000, Calcified Tissue International.

[56]  G. Sledge,et al.  Effects of high dose raloxifene in selected patients with advanced breast carcinoma , 2000, Cancer.

[57]  L. Dirix,et al.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Cauley,et al.  Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass , 2000, Journal of the American Geriatrics Society.

[59]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[60]  P. Delmas,et al.  Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[62]  B. Riggs,et al.  The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. , 1999, Molecular endocrinology.

[63]  B. Gertz,et al.  Pharmacokinetics of alendronate: an overview. , 1999, International journal of clinical practice. Supplement.

[64]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[65]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[66]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[67]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[68]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[69]  S. Cummings,et al.  Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. , 1998, The New England journal of medicine.

[70]  P. Lønning,et al.  In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[72]  T. Powles,et al.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.

[73]  P. Kannus,et al.  Peripheral Quantitative Computed Tomography in Human Long Bones: Evaluation of In Vitro and In Vivo Precision , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  H K Genant,et al.  Noninvasive assessment of bone density and structure using computed tomography and magnetic resonance. , 1998, Bone.

[76]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[77]  R. Eastell.  Treatment of postmenopausal osteoporosis. , 1998, The New England journal of medicine.

[78]  S. Martino,et al.  Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Wark,et al.  Premenopausal Ovariectomy‐Related Bone Loss: A Randomized, Double‐Blind, One‐Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[81]  M. Kumegawa,et al.  Estrogen Inhibits Bone Resorption by Directly Inducing Apoptosis of the Bone-resorbing Osteoclasts , 1997, The Journal of experimental medicine.

[82]  W. Kohrt,et al.  Effects of Exercise Involving Predominantly Either Joint‐Reaction or Ground‐Reaction Forces on Bone Mineral Density in Older Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[83]  R. Rizzoli,et al.  Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. , 1997, The Journal of clinical investigation.

[84]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  D. Kiel,et al.  Bone mass and the risk of breast cancer among postmenopausal women. , 1997, The New England journal of medicine.

[86]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[87]  S. Cummings,et al.  Bone Mineral Density and Risk of Breast Cancer in Older Women: The Study of Osteoporotic Fractures , 1996 .

[88]  Kenneth K Wang,et al.  Esophagitis associated with the use of alendronate. , 1996, The New England journal of medicine.

[89]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[90]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[91]  P. Lønning,et al.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.

[92]  G. Breart,et al.  Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study , 1996, The Lancet.

[93]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[94]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[96]  M. Nozaki,et al.  The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism. , 1995, Maturitas.

[97]  R. Kimble,et al.  Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. , 1995, Endocrinology.

[98]  M. Heineman,et al.  Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. , 1995, The Journal of clinical endocrinology and metabolism.

[99]  J. Graves,et al.  The short- and long-term effects of methotrexate on the rat skeleton. , 1995, Bone.

[100]  J. L. Melton,et al.  Perspectives: How many women have osteoporosis now? , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[101]  P. Strax,et al.  A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[102]  H. Mouridsen,et al.  Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  J A Kanis,et al.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. , 1994, Bone.

[104]  R. Kimble,et al.  Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. , 1993, The Journal of clinical endocrinology and metabolism.

[105]  J. Studd,et al.  The prevention of bone loss in young women treated with GnRH analogs with ‘add‐back’ estrogen therapy , 1993, Obstetrics and gynecology.

[106]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[107]  C. Cooper,et al.  Epidemiology of osteoporosis , 1992, Trends in Endocrinology & Metabolism.

[108]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[109]  L. Kuller,et al.  Reliability and interrelations among serum sex hormones in postmenopausal women. , 1991, American journal of epidemiology.

[110]  J. Hayman,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.

[111]  Takuma Nemoto,et al.  Therapeutic oophorectomy in metastatic breast cancer , 1989, Cancer.

[112]  D. Trichopoulos,et al.  A unifying concept of the aetiology of breast cancer , 1988, International journal of cancer.

[113]  A. Parfitt,et al.  Trabecular bone architecture in the pathogenesis and prevention of fracture. , 1987, The American journal of medicine.

[114]  L. Kuller,et al.  The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women. , 1986, American journal of epidemiology.

[115]  J. Ingle,et al.  Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  S. Lord,et al.  The effects of a community exercise program on fracture risk factors in older women , 2005, Osteoporosis International.

[117]  R. Eastell,et al.  The time course of bone fractures observed in the ATAC (‘Arimidex', Tamoxifen, Alone or in Combination) Trial , 2003 .

[118]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[119]  O. Johnell,et al.  Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: A 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study , 2003, Osteoporosis International.

[120]  F. Cummings.  Evolving uses of hormonal agents for breast cancer therapy. , 2002, Clinical Therapeutics.

[121]  O. Johnell,et al.  Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. , 2002, Bone.

[122]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  C. Cooper,et al.  Risk factors for osteoporosis in Europe , 2001, Journal of Bone and Mineral Metabolism.

[124]  Ray Fleming,et al.  NIH Consensus Panel Addresses Osteoporosis Prevention, Diagnosis, and Therapy , 2000 .

[125]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[126]  C. Blomqvist,et al.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.

[127]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.